Diagnostic assay to assist clinical decisions for unclassified severe combined immune deficiency. Read more about Diagnostic assay to assist clinical decisions for unclassified severe combined immune deficiency.
Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. Read more about Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes.
Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance. Read more about Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance.
Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma. Read more about Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma.
Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. Read more about Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease.
A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia. Read more about A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia.
Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations. Read more about Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.
TA-TMA: state of the art for diagnosis and treatment. Read more about TA-TMA: state of the art for diagnosis and treatment.
A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. Read more about A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.
Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation. Read more about Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation.
